Aktis Oncology, Inc. (AKTS)

NASDAQ

$16.11

$+0.98

(+6.45%)

After-Hours

Aktis Oncology, Inc. (AKTS) Live Price Chart

Last updated: ⁦2026-10-20 22:25:40⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Aktis Oncology, Inc. (AKTS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.11, with a market capitalization of $837.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $34.19. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$837.63M
Open	$15.14
Day's High	$34.19
Day's Low	$0.03
Previous Close	$15.11
Volume	287.46K
Average Volume	365.18K
P/E Ratio	--
52-Week High	$34.19
52-Week Low	$14.72
Dividend Yield	--
Earnings Date	--

Aktis Oncology, Inc. (AKTS) After-Hours Stock Price

Aktis Oncology, Inc. (AKTS) is trading at $16.11 in after-hours trading as of 2026-10-20 21:01:00, up 6.59% ($1.00) from the regular-session close of $15.11.

After-hours trading shows how investors are pricing AKTS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.

Aktis Oncology, Inc. (AKTS) 7-Day Stock Price Change

Over the past seven days, Aktis Oncology, Inc. (AKTS) moved from $18.15 to $16.11, representing a decline of 11.27% ($2.04).

The stock traded between $14.84 and $18.21 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.

The average daily volume was 428.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

AKTS 52-Week Price Position

Position in Range: 7.1%

52W Low$14.72

52W High$34.19

AKTS is currently trading at $16.11, placing it 7.1% of the way from its 52-week low of $14.72 to its 52-week high of $34.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Aktis Oncology, Inc. (AKTS)?

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

Aktis Oncology, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	79
Exchange	NASDAQ
Company Website	https://www.aktisoncology.com

How to Buy Aktis Oncology, Inc. (AKTS) Stock on MEXC

Eligible investors can buy real shares of Aktis Oncology, Inc. (AKTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for AKTS and Place Your Order

Open the RealStocks trading page and search for AKTS. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Aktis Oncology, Inc. (AKTS) stock price today?

Aktis Oncology, Inc. (AKTS) is currently trading at $ 16.11, up 6.59% ($1.00) from the previous close of $ 15.11. Intraday prices update in real time during regular trading hours.

2.Is AKTS stock going up or down today?

As of 2026-10-20 21:01:00, AKTS is trading at $ 16.11, up 6.59% ($1.00) from its previous close of $ 15.11. The stock has traded between $ 0.03 and $ 34.19 during today’s regular session. Past price movements do not guarantee future results.

3.What is AKTS pre-market price?

As of 2026-10-20 21:01:00, AKTS is trading at $ 15.11 in pre-market trading, up 0.01% ($0.00) from the previous close of $ 15.11. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is AKTS after-hours price?

As of 2026-10-20 21:01:00, AKTS is trading at $ 16.11 in after-hours trading, up 6.59% ($1.00) from the regular-session close of $ 15.11. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is AKTS stock trading now?

AKTS trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does AKTS sit relative to its 52-week high and low?

Over the past 52 weeks, AKTS has traded between a low of $ 14.72 and a high of $ 34.19. At $ 16.11, the stock is positioned 7.1% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Aktis Oncology, Inc. in?

Aktis Oncology, Inc. (AKTS) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Aktis Oncology, Inc.'s market capitalization and where is it listed?

Aktis Oncology, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 837.63M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is AKTS valued in terms of P/E ratio and EPS?

AKTS trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Aktis Oncology, Inc. pay a dividend?

Aktis Oncology, Inc. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.